Immucell (ICCC) Change in Accured Expenses (2010 - 2025)

Immucell (ICCC) has 16 years of Change in Accured Expenses data on file, last reported at -$22606.0 in Q4 2025.

• Quarterly Change in Accured Expenses rose 7.31% year-over-year to -$22606.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$195254.0 (down 153.85% YoY) and the FY2025 annual result came in at -$195254.0, down 153.85% from the prior year.
• Change in Accured Expenses declined to -$22606.0 in Q4 2025, from $133036.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $430259.0 in Q2 2024 to a low of -$531203.0 in Q1 2025.
• A 5-year average of $45586.0 and a median of $8302.0 in 2022 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 310.35% in 2025, down 2758.67% in 2025.
• Tracing ICCC's Change in Accured Expenses over 5 years: stood at $367502.0 in 2021, then decreased by 12.31% to $322265.0 in 2022, then declined by 21.65% to $252488.0 in 2023, then sank by 109.66% to -$24389.0 in 2024, then advanced by 7.31% to -$22606.0 in 2025.
• The last three Change in Accured Expenses figures came in at -$22606.0 (Q4 2025), $133036.0 (Q3 2025), and $225519.0 (Q2 2025), per Business Quant data.